Medical Weight Loss: The GLP-1 Science Explained
Medical weight loss programs have transformed how physicians approach obesity and metabolic disease. Unlike commercial diet plans, physician-supervised medical weight loss at Skin Art MD in Burnaby combines evidence-based pharmacotherapy with individualized lifestyle guidance — addressing the biology of weight regulation, not simply willpower.
If you have heard about GLP-1 class medications and wondered whether they might be right for you, this article breaks down the actual science: how this class of medication works at the cellular level, what a physician looks at, and how candidacy is assessed. Learn more about Medical Weight Loss
Our approach at Skin Art MD begins with a thorough physician consultation — because no medically sound program starts with a prescription alone.
What Is Medical Weight Loss?
Medical weight loss refers to physician-supervised strategies for achieving and maintaining clinically meaningful weight reduction, typically defined as five to ten percent or more of initial body weight.
This threshold is significant: research consistently demonstrates that even modest reductions can substantially lower cardiometabolic risk — improving blood pressure, fasting glucose, HbA1c, and lipid panels in parallel with the number on the scale. In contemporary practice, comprehensive medical weight loss programs integrate:
- GLP-1 receptor agonist pharmacotherapy — the primary pharmacological tool discussed here
- Nutritional counseling tailored to individual metabolic profile
- Behavioral support to sustain habit change over time
- Ongoing monitoring of metabolic biomarkers and medication tolerance This is not a shortcut. It is a medical intervention governed by the same principles of informed consent, contraindication screening, and outcome monitoring as any clinical procedure.
Mechanism of Action: How GLP-1 Receptor Agonists Work
The GLP-1 Hormone — A Cellular Primer
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by L-cells in the distal small intestine and colon in response to nutrient ingestion. It exerts multiple coordinated physiological actions:
- Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner — meaning it triggers insulin release only when blood glucose is elevated, a built-in safety mechanism that reduces hypoglycemia risk compared to older agents
- Suppresses glucagon release from pancreatic alpha cells, reducing hepatic glucose output
- Slows gastric emptying, prolonging satiety signals from the gut
- Acts centrally on hypothalamic appetite circuits — specifically the arcuate nucleus and nucleus tractus solitarius — to reduce food-seeking behavior and total caloric intake In individuals with obesity, the normal postprandial GLP-1 surge is often blunted. GLP-1 receptor agonists (GLP-1 RAs) bypass this deficit by delivering pharmacological GLP-1 signaling at receptors throughout the body, with a substantially longer half-life than endogenous GLP-1 — which is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4).
Why the Weekly GLP-1 Agents Behave Differently
The GLP-1 receptor agonists used for weight management are engineered analogues of the human hormone: a fatty-acid side chain lets the molecule bind reversibly to albumin, which extends its half-life to roughly a week and permits once-weekly subcutaneous dosing — a practical advantage over earlier daily-injection agents in the same class.
At weight-management dosing, the central nervous system effects of this class become particularly pronounced. Neuroimaging studies have demonstrated reduced activation in dopaminergic reward-processing brain regions in response to food cues — attenuating not only physiological hunger but also the hedonic drive to eat.
Patients often describe this as food simply feeling less compelling, rather than requiring willpower to resist.
The weight-management indication is a distinct indication. It applies to adults with obesity, or with overweight accompanied by at least one weight-related comorbidity. Lower-dose formulations of the same class are used for type 2 diabetes, with different dosing and different monitoring. That distinction matters clinically: dose, indication and monitoring protocol are not interchangeable between diabetic and non-diabetic populations. Physician oversight is not optional. Book a Consultation
What the Published Literature Establishes
Effect Size
Randomised, placebo-controlled work published in the New England Journal of Medicine established that weekly GLP-1 receptor agonist therapy produces substantially greater weight reduction than placebo in adults with overweight or obesity and no diabetes. We do not quote trial figures here: individual response varies widely, and a number lifted out of a trial population is not a forecast for any one patient. Your physician will discuss what the evidence supports for your situation.
The Discontinuation Question
The same body of work examined what happens when therapy is withdrawn after an initial treatment period. Participants who stopped regained a substantial share of the weight they had lost, while those who continued maintained their reductions.
This finding carries critical implications for patient counseling: medical weight loss with GLP-1 therapy is a sustained intervention, not a finite course.
Weight regain after stopping is biologically expected and should be discussed at the outset.
Cardiovascular Outcomes
A large cardiovascular outcomes trial in adults with overweight or obesity and established cardiovascular disease but without diabetes reported a reduction in major adverse cardiovascular events versus placebo — repositioning GLP-1 therapy from a metabolic niche agent to an intervention with broader cardiometabolic relevance.
Taken together, this class is among the more rigorously studied areas of metabolic pharmacotherapy.
Comparing GLP-1 Therapy to Adjacent Approaches
Understanding where GLP-1 therapy fits relative to alternatives helps patients make genuinely informed decisions: | Approach | Mechanism | Average Weight Loss | Durability | Physician Required |
| --- |
|---|
| --- |
| --- |
| --- |
| Lifestyle modification alone | Caloric deficit, behavioral | Discussed at consultation | Low without ongoing support | Recommended |
| GI lipase inhibitor | Reduces dietary fat absorption | Discussed at consultation | Moderate | Yes |
| Daily GLP-1 receptor agonist | GLP-1 RA — daily injection | Discussed at consultation | Moderate | Yes |
| Weekly GLP-1 receptor agonist | GLP-1 RA — weekly injection | Discussed at consultation | Higher (with continuation) | Yes — physician |
| Bariatric surgery | Anatomical restriction / malabsorption | Discussed with a surgical team | High | Yes — surgical team | Weekly GLP-1 therapy sits between lifestyle-only approaches and surgical intervention. Lipase inhibitors are limited in practice by gastrointestinal tolerability, and many patients discontinue them. Daily GLP-1 injection has a more modest effect than weekly dosing in the published literature. Oral formulations in this class are in development. Which option is appropriate is a clinical judgement, not a ranking.
Candidate Evaluation: Who Qualifies?
At Skin Art MD, physician evaluation for medical weight loss is conducted by Dr. Sharon Fong, our licensed physician specializing in aesthetic medicine and metabolic health. The evaluation process follows established obesity medicine guidelines:
Inclusion Criteria -
BMI ≥30 kg/m² (obesity classification), or
- BMI 27–29.9 kg/m² with at least one weight-related comorbidity: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or non-alcoholic fatty liver disease
- Adult patients with realistic expectations and genuine commitment to behavioral co-management
Contraindications and Cautions
GLP-1 receptor agonists are contraindicated or require careful consideration in the following contexts:
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) — this is a black box warning for the entire GLP-1 RA class, based on preclinical rodent thyroid C-cell findings
- Active pancreatitis or history of severe pancreatitis — GLP-1 therapy should be avoided
- Pregnancy or planned pregnancy — weight loss pharmacotherapy is not appropriate during gestation
- Severe renal impairment beyond specified thresholds
- Significant GI motility disorders The evaluation also screens for eating disorder history — GLP-1-induced appetite suppression requires careful navigation in patients with a history of restrictive eating patterns — as well as concurrent medications with interaction potential and baseline thyroid function. Book a Consultation to begin a full physician assessment.
What to Expect: The Treatment Timeline
Patients in Burnaby entering the Skin Art MD medical weight loss program follow a structured, monitored protocol:
Phase 1 — Assessment (Week 0): Comprehensive consultation with history review, BMI calculation, and relevant laboratory work including thyroid panel, metabolic panel, and HbA1c. Full discussion of realistic expectations, timeline, and behavioral framework. Phase 2 — Initiation (Weeks 1–4): Low starting dose to minimize GI side effects. Nausea — the most common early complaint — typically diminishes within two to four weeks as gastric accommodation develops. Phase 3 — Dose Escalation (Months 1–5): Gradual titration per clinical response and individual tolerability. Most patients reach their maintenance dose over sixteen to twenty weeks. Phase 4 — Maintenance and Monitoring (Month 6 Onward): Regular check-ins to assess weight trajectory, metabolic markers, side effect profile, and behavioral adherence. Dose adjustments made as clinically indicated. Phase 5 — Long-term Strategy: Given what the discontinuation data show about weight regain after therapy stops, every program at Skin Art MD includes an honest, individualized conversation about sustained therapy versus transition planning. Many of our patients in the Greater Vancouver area begin noticing meaningful changes in appetite and energy patterns within the first four to six weeks, with significant weight changes typically visible at the three-month mark — though individual results vary based on metabolic baseline, dietary adherence, and dose response.
Limitations and Adverse Effects
No medication is without limitations. Common adverse effects of GLP-1 RAs include:
- Nausea — most common, particularly during dose escalation; manageable with dose timing, meal composition adjustments, and graduated titration
- Constipation — addressed with adequate hydration, dietary fiber, and occasionally gentle stool softeners
- Reduced appetite — while therapeutically intended, can occasionally result in insufficient protein or micronutrient intake if dietary quality is not monitored
- Injection site reactions — typically mild and transient Rare but serious adverse events to remain aware of:
- Acute pancreatitis — discontinue immediately if symptoms develop (severe epigastric pain radiating to the back)
- Gallbladder disease — cholelithiasis risk increases with rapid weight loss by any mechanism, not specific to GLP-1 therapy
- Potential ocular signals — regulatory agencies including Health Canada are actively monitoring emerging reports; patients with pre-existing eye disease should discuss this with their physician Cost and medication access represent real-world barriers for many patients. GLP-1 medication at weight-management dosing is not universally covered by BC provincial drug plans, and supply has periodically been constrained. A physician consultation at Skin Art MD will address current coverage options. Contact us for current pricing.
Why Choose Skin Art MD for Medical Weight Loss?
Clinics across the Greater Vancouver area offer weight loss programs. What distinguishes the physician-led approach at Skin Art MD:
Physician-led, not protocol-driven. Dr. Fong's registration means your care is governed by the same regulatory standards as any licensed BC physician — not a standardized algorithm operated by non-physician staff. Integrated aesthetic and metabolic perspective. Weight loss affects skin laxity, facial volume, and body contour. At Skin Art MD in Burnaby, we think holistically about what physical transformation means for you — and can address skin and body contouring considerations as part of a comprehensive care plan. Bilingual care. Our team serves English- and Mandarin-speaking patients. For patients in the Metro Vancouver Chinese community, navigating medical conversations in your preferred language matters. 我们提供普通话和英语双语医疗服务。 Genuinely personalized. Patients often tell us that previous programs felt generic. Our initial consultation is a thorough, individualized conversation — not a checkbox exercise. Accessible Burnaby location. Conveniently located near Metrotown, easily reached from across Burnaby, New Westminster, Richmond, and Vancouver. Book your complimentary consultation at Skin Art MD
Frequently Asked Questions
How is medical weight loss different from ordering the medication through an online pharmacy? Physician oversight provides systematic contraindication screening, appropriate dose selection, monitoring for adverse effects, and integration with behavioral support.
Prescriptions issued without proper in-person evaluation carry meaningful medical risk and are increasingly subject to regulatory action in Canada. How quickly will I see results? Results vary significantly by individual — baseline metabolism, dietary patterns, dose tolerance, and genetic factors all influence the trajectory. In the published literature, meaningful weight change was typically observed within the first few months of reaching an effective dose. Is long-term GLP-1 use safe? The cardiovascular outcomes work followed participants for approximately three years and reported sustained benefit with an acceptable safety profile. Longer-horizon data continue to accumulate. At Skin Art MD, ongoing benefit-risk reassessment is built into the program structure. Will I regain weight if I stop the medication? The discontinuation data clearly show that a significant proportion of weight lost returns after therapy stops — this is biologically expected. GLP-1 therapy modulates appetite set-points that trend back toward baseline when medication is withdrawn. Long-term strategy planning is therefore an explicit component of our program, not an afterthought. Can I combine this program with aesthetic treatments? Many Skin Art MD patients integrate medical weight loss with body contouring or skin tightening procedures. Sequence and timing depend on individual goals and are discussed during consultation. Does BC insurance cover GLP-1 medication for weight loss? Coverage varies significantly by plan and differs from the diabetes indication. Our team can guide you through documentation requirements and any applicable appeal processes. Contact us for current pricing and coverage guidance.
Next Steps
If you have read this far, you are doing precisely what an informed patient should: understanding the biology before making a decision.
The next step is a physician-level conversation tailored to your specific health history, goals, and current medications. At Skin Art MD in Burnaby, medical weight loss consultations are conducted directly by Dr. Fong — not delegated to non-physician staff.
Consultation spots are limited; we recommend booking in advance to secure your preferred time.
Ready to See What Medical Weight Loss Can Do for You?
Our medical team at Skin Art MD in Burnaby is ready to create your personalized treatment plan. Book your complimentary consultation today — available in English and Chinese.
This article is for educational purposes only and does not constitute medical advice. Please consult with a qualified healthcare professional before undergoing any treatment.
